DLBCL
Advertisement
A study published in The Laryngoscope assessed different treatment modalities for patients with sinonasal diffuse large ...
Interim 3′-deoxy-3′-[18F]fluorothymidine (iFLT) PET/CT was superior to interim 18F-fluorodeoxyglucose (iFDG) PET/CT ...
Short diagnosis-to-treatment (DTI) and circulating tumor DNA (ctDNA) levels in patients with diffuse large B-cell ...
A study published in Cancer Medicine found that surgery may be a beneficial treatment option for certain patients with ...
The risk of second malignant neoplasms (SMNs) in patients with diffuse large B-cell lymphoma (DLBCL) may vary depending ...
A study presented at the 2020 ASH Annual Meeting found that loncastuximab, a humanized anti-CD19 antibody, had ...
Guidelines from the World Health Organization and National Comprehensive Cancer Network recommend that all patients with ...
AUTO3 is a chimeric antigen receptor (CAR) T-cell targeting CD19/22 with limited duration of PD-1 blockade. A study ...
A study presented at the 2020 ASH Annual Meeting found that the efficacy of selinexor in patients with ...
Researchers assessed the use of a next-generation sequencing (NGS)-based minimal residual disease (MRD) assay for early ...
A real-world study presented at the 2020 ASH Annual Meeting observed no significant survival differences in patients ...
Acalabrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was ...
A study presented at the 2020 ASH Annual Meeting assessed whether there was a survival difference between Hispanic (HI) ...
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus lenalidomide improved response rates ...
Real-world data showed a high unmet medical need among older patients with diffuse large B-cell lymphoma (DLBCL): Up to ...
Up to one-quarter of older Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) do not receive any therapy. ...
A study presented at the 2020 ASH Annual Meeting found that R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...
A study presented at the 2020 ASH Annual Meeting found that tafasitamab in combination with rituximab mediates increased ...
Barriers within oncology systems can impede patient-centered care coordination and delivery in those with ...
The combination of ibrutinib (Imbruvica®), lenalidomide (Revlimid®), and rituximab (Rituxan®) had a manageable safety ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.